Recombinant Mouse Omega-3 fatty acid receptor 1 (O3far1)

What is mouse O3far1 and what are its common alternative designations in scientific literature?

Mouse O3far1 (Omega-3 fatty acid receptor 1) is a G-protein coupled receptor that serves as a primary sensor for medium and long-chain free fatty acids, particularly omega-3 fatty acids. In scientific literature, it is commonly designated as GPR120 or G-protein coupled receptor 120 . The receptor signals via a G(q)/G(11)-coupled pathway and mediates robust anti-inflammatory effects, especially in macrophages and adipocytes . This receptor represents a crucial link between dietary omega-3 fatty acid intake and downstream physiological responses.

How does mouse O3far1 signal transduction work in response to omega-3 fatty acid binding?

When omega-3 fatty acids bind to O3far1, the receptor activates and recruits β-arrestin2 protein as its first downstream mediator. This activation initiates a signaling cascade where β-arrestin2 subsequently recruits TAB1/2 (TGF-β activated kinase 1 binding proteins) from TLR2/4 and TNF-α signaling pathways . This recruitment disassembles inflammatory cascades by promoting the dephosphorylation of TAK1 (TGF-β activated kinase 1), which acts as a nodal protein in multiple inflammatory signaling pathways . This mechanism effectively inhibits the pro-inflammatory signaling, contributing to the anti-inflammatory effects of omega-3 fatty acids.

In which mouse tissues is O3far1 expression documented and what are the tissue-specific differences in expression levels?

O3far1/GPR120 expression has been documented in multiple mouse tissues. Research has confirmed its presence in liver, skeletal muscle, adipose tissue, aorta, and hypothalamus . Additionally, GPR120 has been detected in retinal tissue, where its expression can be modulated by dietary interventions such as flaxseed oil supplementation . Comparative tissue expression analysis shows that O3far1 is prominently expressed in metabolically active tissues, suggesting its importance in energy homeostasis and inflammatory regulation across multiple organ systems.

How can the fat-1 transgenic mouse model be utilized for O3far1 receptor research?

The fat-1 transgenic mouse model expresses the C. elegans fat-1 gene, which encodes an n-3 fatty acid desaturase that converts omega-6 to omega-3 fatty acids—a capability naturally absent in mammals . This model offers significant advantages for studying O3far1 function as it:

• Eliminates confounding factors associated with dietary supplementation

• Creates a physiologically relevant omega-3 rich environment

• Maintains consistent omega-3 enrichment from embryonic development throughout the animal's lifespan

• Achieves a balanced n-6/n-3 fatty acid ratio (approximately 1:1) in all tissues

Researchers can use this model to study O3far1 activation and signaling in vivo without the variables introduced by dietary manipulation, providing a well-controlled experimental system for investigating receptor-mediated effects .

What are the methodological considerations when establishing O3far1 knockout models versus using pharmacological inhibitors?

When studying O3far1 function, researchers must carefully consider the relative advantages and limitations of genetic versus pharmacological approaches:

For comprehensive O3far1 studies, a combined approach using both methodologies may provide the most robust validation of experimental findings.

What are the optimal methods for detecting and quantifying O3far1 expression in mouse tissues?

For reliable detection and quantification of O3far1 in mouse tissues, researchers should employ a multi-modal approach:

• mRNA quantification: RT-qPCR using validated primers specific for mouse O3far1/GPR120. Normalization should be performed against at least three stable reference genes such as GAPDH, β-actin, and 18S rRNA.

• Protein detection: Western blot analysis using validated antibodies against mouse O3far1/GPR120. Validation of antibody specificity using knockout tissue or siRNA-treated samples is essential to ensure signal specificity.

• Tissue localization: Immunohistochemistry or immunofluorescence with appropriate controls, including blocking peptides and secondary-only controls. This approach enables visualization of receptor distribution within tissue compartments .

• Quantitative assessment: ELISA-based methods provide a more quantitative measure of O3far1 levels in tissue homogenates or cell culture supernatants. Commercial kits with a detection range of 0.625-40 ng/ml and sensitivity of approximately 0.322 ng/mL are available for rat O3far1 and similar approaches can be adapted for mouse samples.

When analyzing retinal tissue specifically, researchers have successfully employed all three approaches (mRNA quantification, protein content by Western blot, and immunohistochemical photomicrography) to evaluate receptor presence and distribution .

What are the critical considerations for producing functional recombinant mouse O3far1 protein?

Production of functional recombinant mouse O3far1 presents several technical challenges due to its nature as a transmembrane G-protein coupled receptor. Critical considerations include:

• Expression system selection: Mammalian expression systems (HEK293, CHO cells) are preferred over bacterial or insect cell systems to ensure proper post-translational modifications and folding.

• Solubilization strategy: As a seven-transmembrane domain protein, O3far1 requires careful solubilization. Mild detergents like n-dodecyl-β-D-maltoside (DDM) or digitonin are recommended to maintain native conformation.

• Affinity tag placement: N-terminal tags are generally preferred over C-terminal tags to avoid interference with G-protein coupling domains. Cleavable tags (e.g., TEV protease sites) allow tag removal after purification.

• Functional validation: Ligand binding assays using radiolabeled or fluorescently labeled omega-3 fatty acids should be performed to confirm that the recombinant protein retains binding capacity.

• Storage conditions: The purified protein should be stored in the presence of stabilizing agents such as glycerol (10-20%) at -80°C, with minimal freeze-thaw cycles to preserve activity.

Researchers should validate the functionality of produced recombinant O3far1 through downstream signaling assays, such as calcium mobilization or β-arrestin recruitment assays, to ensure the protein maintains its native signaling capabilities.

How can researchers effectively study the interaction between O3far1 and β-arrestin2 in inflammatory signaling?

To study the critical interaction between O3far1 and β-arrestin2 in inflammatory signaling, researchers should consider these methodological approaches:

• Co-immunoprecipitation (Co-IP): Use antibodies against O3far1 to pull down the receptor complex and detect β-arrestin2 association by Western blot. This approach can be performed in native tissues or cell culture systems exposed to omega-3 fatty acids.

• Proximity ligation assay (PLA): This technique allows visualization of protein-protein interactions in situ with high sensitivity. Using specific antibodies against O3far1 and β-arrestin2, researchers can detect their interaction as fluorescent spots when the proteins are in close proximity.

• BRET/FRET analysis: Bioluminescence/Fluorescence Resonance Energy Transfer techniques using O3far1 and β-arrestin2 fusion constructs with appropriate donor/acceptor pairs enable real-time monitoring of interactions in living cells.

• siRNA knockdown studies: Selective knockdown of β-arrestin2 followed by analysis of TAK1 phosphorylation status upon O3far1 stimulation helps establish the dependency of anti-inflammatory effects on the β-arrestin2 pathway .

• Phosphorylation analysis: Tracking the phosphorylation status of downstream targets like TAK1 in response to O3far1 activation provides insights into pathway functionality. This can be achieved through phospho-specific antibodies in Western blotting or ELISA-based assays.

The anti-inflammatory effects of O3far1 activation involve inhibition of TAK1 through a β-arrestin2 (ARRB2)/TAB1 dependent mechanism , which can be verified by examining the recruitment of TAB1/2 from TLR2/4 and TNF-α pathways .

What experimental approaches can resolve contradictory findings regarding O3far1-mediated effects on immune function?

Resolving contradictory findings regarding O3far1-mediated effects on immune function requires systematic experimental approaches that account for context-dependent signaling:

• Tissue-specific analysis: Different tissues may exhibit distinct O3far1 signaling patterns. Researchers should compare O3far1 signaling in macrophages, adipocytes, hepatocytes, and other relevant cell types to identify tissue-specific responses .

• Ligand specificity investigation: Different omega-3 fatty acids (EPA, DHA, ALA) may activate O3far1 with varying efficacies and trigger distinct downstream pathways. Dose-response studies with pure fatty acids can help clarify these differences.

• Temporal signaling dynamics: Short-term versus long-term activation of O3far1 may yield different outcomes. Time-course experiments capturing both early (minutes to hours) and late (days) responses provide a comprehensive understanding of signaling dynamics.

• Pathway crosstalk analysis: O3far1 signaling does not operate in isolation. Researchers should evaluate interactions with other pathways, such as interferon signaling, which may be impaired by omega-3 fatty acids .

• Immunological challenge models: Studies have shown that while omega-3 fatty acids have anti-inflammatory effects, they may impair resistance to certain infections . Using challenge models with bacterial (e.g., Listeria monocytogenes) or viral pathogens can help resolve these seemingly contradictory effects.

For example, research has shown that omega-3 fatty acids may downmodulate the IFN-γ-mediated STAT1 signaling pathway by decreasing STAT1 phosphorylation , potentially through disrupted interaction between the IFN-γ receptor and lipid rafts. This mechanism may explain both anti-inflammatory benefits and potential immunosuppressive effects.

How does O3far1 signaling differ in normal versus pathological states like obesity and inflammation?

O3far1 signaling undergoes significant alterations between normal physiological conditions and pathological states:

In obesity models, flaxseed oil supplementation has been shown to positively modulate GPR120 expression in retinal tissue compared to high-fat diet groups , suggesting dietary intervention can restore receptor function in pathological states. This modulation may contribute to protection against diabetic retinopathy through disruption of pro-inflammatory status in the retina .

What is the current understanding of O3far1's role in regulating metabolism and inflammation in different mouse models?

Current understanding of O3far1's role in regulating metabolism and inflammation has been advanced through various mouse models:

The seemingly contradictory effects of O3far1 signaling across different models highlight the context-dependent nature of omega-3 fatty acid signaling, which researchers must consider when designing studies and interpreting results.

What are the recommended approaches for evaluating O3far1-associated lipid raft dynamics and receptor signaling?

Evaluating O3far1-associated lipid raft dynamics and receptor signaling requires specialized techniques:

• Detergent-resistant membrane isolation: Sucrose gradient ultracentrifugation can separate detergent-resistant membrane fractions (lipid rafts) from non-raft membrane regions. Western blot analysis of these fractions for O3far1 and canonical raft markers (Caveolin-1, Flotillin) reveals receptor distribution.

• Super-resolution microscopy: Techniques such as STORM (Stochastic Optical Reconstruction Microscopy) or STED (Stimulated Emission Depletion) microscopy enable visualization of O3far1 clustering in membrane microdomains at nanoscale resolution, revealing dynamic receptor organization beyond the diffraction limit.

• FRAP analysis: Fluorescence Recovery After Photobleaching studies using fluorescently-tagged O3far1 can quantify receptor mobility within membrane regions, providing insights into how omega-3 fatty acids alter receptor dynamics.

• Methyl-β-cyclodextrin (MβCD) treatment: This cholesterol-depleting agent disrupts lipid rafts and can be used to assess the raft-dependency of O3far1 signaling. Comparing signaling outcomes before and after MβCD treatment reveals raft-dependent components.

• Lipidomic profiling: Mass spectrometry-based lipidomics of isolated membrane fractions can characterize the lipid environment surrounding O3far1, particularly how dietary omega-3 supplementation alters this microenvironment.

Research has shown that omega-3 fatty acids may disrupt the interaction between receptors (such as the IFN-γ receptor) and lipid rafts , which could explain some of their immunomodulatory effects. Similar mechanisms may apply to O3far1 itself, potentially creating feedback loops in signaling.

How can researchers effectively differentiate between GPR40 and GPR120 (O3far1) mediated effects in complex biological systems?

Differentiating between GPR40 and GPR120 (O3far1) mediated effects presents a significant challenge due to overlapping ligand specificity. Researchers should employ these approaches:

• Selective agonists/antagonists: Use receptor-specific synthetic agonists like TUG-891 (O3far1-selective) or TAK-875 (GPR40-selective) to distinguish receptor-specific effects. Careful dose-response studies are essential as selectivity can be lost at higher concentrations.

• siRNA/shRNA knockdown: Selective silencing of either receptor allows attribution of remaining effects to the non-targeted receptor. Sequential or simultaneous knockdown provides comprehensive pathway dissection.

• CRISPR/Cas9 receptor editing: Generate cell lines or animal models with specific receptor knockout to conclusively attribute effects to either GPR40 or O3far1.

• Receptor expression profiling: Comprehensive tissue-specific expression analysis helps identify regions where only one receptor predominates, simplifying interpretation of effects in those tissues.

• Downstream signaling discrimination: Although both receptors couple to G-proteins, their downstream pathways differ. O3far1 uniquely engages β-arrestin2 pathways leading to TAB1/TAK1 interaction , while GPR40 primarily signals through PLCβ/IP3/calcium pathways. Monitoring these distinct downstream events helps differentiate receptor activation.

Research in retinal tissue has demonstrated that both GPR120 and GPR40 are present and can be modulated by dietary interventions , highlighting the importance of careful discrimination between their effects in physiological contexts.

How do findings from mouse O3far1 studies translate to understanding human O3FAR1 physiology and pathology?

Translating mouse O3far1 research to human applications requires careful consideration of cross-species similarities and differences:

• Sequence homology: Mouse O3far1 shares approximately 85% amino acid sequence identity with human O3FAR1, with higher conservation in the ligand-binding and G-protein coupling domains. This suggests reasonably good translational potential for basic mechanistic studies.

• Expression pattern differences: While both mouse and human express O3FAR1/GPR120 in adipose tissue, macrophages, and pancreatic cells, species-specific expression differences exist in other tissues. Researchers should validate expression patterns when extrapolating from mouse to human contexts.

• Signaling pathway conservation: The core O3far1 signaling through β-arrestin2 and subsequent TAK1 inhibition appears conserved between species , supporting translational relevance of anti-inflammatory mechanisms observed in mice.

• Pharmacological response variations: Human O3FAR1 may exhibit different ligand affinities and pharmacological responses compared to mouse O3far1. Dose-response relationships established in mouse models should be validated in human cell systems.

• Metabolic context differences: Mice have different baseline metabolic rates and lipid metabolism compared to humans. This necessitates careful interpretation of metabolic phenotypes associated with O3far1 modulation.

For maximizing translational value, researchers should consider parallel studies in mouse models and human cell systems, and where possible, validate key findings using human tissue samples or humanized mouse models.

What are the most promising research directions for developing O3far1-targeted therapeutic approaches?

Based on current understanding of O3far1 biology, several promising research directions for therapeutic development emerge:

• Selective agonist development: Design of small molecule agonists that selectively activate O3far1 without affecting GPR40 could leverage anti-inflammatory benefits without potentially confounding metabolic effects. Focus should be on compounds that effectively recruit β-arrestin2 to achieve anti-inflammatory outcomes.

• Tissue-targeted delivery approaches: Develop delivery systems that can target O3far1 modulators to specific tissues (e.g., adipose tissue for metabolic disease, retina for diabetic retinopathy , or lung for respiratory inflammation) to maximize therapeutic index.

• Combination therapy exploration: Investigate synergistic effects between O3far1 agonists and established anti-inflammatory or insulin-sensitizing drugs. This could potentially allow lower doses of both agents with improved efficacy and reduced side effects.

• Biomarker identification: Develop biomarkers that predict responsiveness to O3far1-targeted therapies, enabling patient stratification for precision medicine approaches.

• Temporal modulation strategies: Given the complex dual roles of O3far1 in inflammation and immunity , explore pulsed or cyclical treatment regimens that capture beneficial anti-inflammatory effects while minimizing potential immunosuppressive consequences.

• Dietary intervention optimization: Determine optimal omega-3 fatty acid compositions and ratios that preferentially activate O3far1 beneficial signaling. The fat-1 transgenic mouse model suggests that a balanced n-6/n-3 ratio (approximately 1:1) may be ideal .

Researchers should remain mindful of potential adverse effects, as studies have shown that excessive omega-3 fatty acid intake may impair certain immune responses , highlighting the need for careful therapeutic window definition.